EU/3/18/2046

About

On 31 July 2018, orphan designation (EU/3/18/2046) was granted by the European Commission to Italfarmaco S.p.A., Italy, for givinostat for the treatment of Becker muscular dystrophy.

Key facts

Active substance
Givinostat
Disease / condition
Treatment of Becker muscular dystrophy
Date of decision
31/07/2018
Outcome
Positive
Orphan decision number
EU/3/18/2046

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Italfarmaco S.p.A.
Via dei Lavoratori 54
20092 Cinisello Balsamo (MI)
Italy
Tel. + 39 0264 4325 84
Fax + 39 0264 4335 54
E-mail: info@italfarmaco.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating